Halozyme Therapeutics (HALO) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

Zacks
Zacks kaynağında aç
Halozyme Therapeutics (HALO) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

The upcoming report from Halozyme Therapeutics (HALO) is expected to reveal quarterly earnings of $2.29 per share, indicating an increase of 33.1% compared to the year-ago period. Analysts forecast revenues of $480.68 million, representing an increase of 35.7% year over year.

The consensus EPS estimate for the quarter has undergone an upward revision of 2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.

Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.

While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.

Given this perspective, it's time to examine the average forecasts of specific Halozyme Therapeutics metrics that are routinely monitored and predicted by Wall Street analysts.

Based on the collective assessment of analysts, 'Revenues- Revenues under collaboration agreements' should arrive at $26.30 million. The estimate points to a change of +9.6% from the year-ago quarter.

Analysts predict that the 'Revenues- Product sales, net' will reach $127.75 million. The estimate suggests a change of +35.6% year over year.

It is projected by analysts that the 'Revenues- Royalties' will reach $326.63 million. The estimate indicates a year-over-year change of +38.4%.

Analysts' assessment points toward 'Product sales, net- Device partnered product sales' reaching $12.18 million. The estimate indicates a year-over-year change of +28.3%.

The combined assessment of analysts suggests that 'Product sales, net- Bulk rHuPH20 sales' will likely reach $45.22 million. The estimate points to a change of +39.2% from the year-ago quarter.

According to the collective judgment of analysts, 'Product sales, net- Proprietary product sales' should come in at $65.64 million. The estimate suggests a change of +25.7% year over year.

View all Key Company Metrics for Halozyme Therapeutics here>>>

Shares of Halozyme Therapeutics have experienced a change of +17.2% in the past month compared to the -2% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), HALO is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research